Finance

Lists
CGEM:NASDAQ
Cullinan Therapeutics Inc
$20.59
-1.95%
(-0.41) 1D
$21.11
+2.53% (+0.52)
After hours
Closed: Sep 11, 4:00:01 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for CGEM...
Open
$21.16
High
$21.34
Low
$20.10
Mkt. cap
1.33B
Avg. vol.
707.41K
Volume
1.09M
52-wk high
$23.19
52-wk low
$5.68
EPS
-$3.41
Beta
0.01
Shares outstanding
64.36M
No. of employees
109
Open
$21.16
High
$21.34
Low
$20.10
Mkt. cap
1.33B
Avg. vol.
707.41K
Volume
1.09M
52-wk high
$23.19
52-wk low
$5.68
EPS
-$3.41
Beta
0.01
Shares outstanding
64.36M
No. of employees
109
News stories
From web sources and news partners
About Cullinan Therapeutics Inc
CEO-
Employees109
Founded2016
Headquarters-
SectorBiotechnology
Websitecullinantherapeutics.com
Analyst ratings
Based on 10 analysts giving stock ratings to CGEM in the past 3 months
Strong buy
Buy
10
Hold
0
Sell
0
12-month forecast
Based on 10 Wall Street analysts offering 12 month price targets for CGEM in the last 3 months.
Highest
Current $20.59
$47.00 (+128.27%)
Average
$34.11 (+65.66%)
Lowest
$27.00 (+31.13%)
Analyst
Recommendation
Action
Price target
Projected
Date
Sean Laaman
Morgan Stanley
Buy
Reiterated
$30.00
+45.7%
08/17/2026
David Dai
UBS
Buy
Maintained
$27.00
+31.1%
08/17/2026
Robert Burns
H.C. Wainwright
Buy
Reiterated
$30.00
+45.7%
08/17/2026
Alex Thompson CFA
Stifel Nicolaus
Buy
Maintained
$28.00
+36%
08/13/2026
Kaveri Pohlman
Clear Street
Buy
Reiterated
$47.00
+128.3%
08/14/2026
Matt Phipps
William Blair
Buy
Reiterated
-
-
08/13/2026
Samantha Semenkow
Citi
Buy
Maintained
$33.00
+60.3%
08/06/2026
Boris Peaker
JonesTrading
Buy
Maintained
$36.00
+74.8%
08/06/2026
Robert Driscoll
Wedbush
Buy
Reiterated
$37.00
+79.7%
07/29/2026
Julian Harrison
BTIG
Buy
Reiterated
$39.00
+89.4%
07/29/2026
Marc Frahm
TD Cowen
Buy
Maintained
-
-
06/10/2026
Soumit Roy
JonesTrading
Buy
Maintained
$36.00
+74.8%
04/06/2026
Bradley Canino
Guggenheim
Buy
Reiterated
$30.00
+45.7%
03/10/2026
Last report
Aug 6, 2026
Fiscal period
Q2 2026
EPS / Est. (USD)
-$0.81 / -$0.85
+4.85%beat
Revenue / Est. (USD)
- / 0.00
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
41.97M
42.94M
42.12M
44.44M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
13.63M
12.31M
11.57M
12.82M
Operating expense
55.60M
55.26M
53.70M
57.25M
Total operating expenses
55.60M
55.26M
53.70M
57.25M
Operating income
-55.60M
-55.26M
-53.70M
-57.25M
Other non operating income
-108.00K
-69.00K
-62.00K
-98.00K
EBT including unusual items
-50.61M
-50.71M
-49.66M
-53.70M
EBT excluding unusual items
-50.61M
-50.71M
-49.66M
-53.70M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-50.61M
-50.71M
-49.66M
-53.70M
Net profit margin
-
-
-
-
Earnings per share
-0.77
-0.77
-0.75
-0.81
Interest and investment income
5.09M
4.62M
4.10M
3.65M
Interest expense
-
-
-
-
Net interest expenses
5.09M
4.62M
4.10M
3.65M
Depreciation and amortization charges
-
-
-
-
EBITDA
-55.52M
-55.18M
-53.62M
-57.18M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps